The Pain Management Reimbursement Landscape
The procedure hasn't changed. Where you do it — and how you contract it — decides the margin.
In interventional pain, the economics live less in the visit and more in the procedure, the site of service, and the ancillaries that ride alongside it.
An epidural steroid injection, a facet or medial-branch block, and radiofrequency ablation are the economic engine of a pain practice — yet the allowed amount for the identical CPT swings dramatically across the physician office, the ambulatory surgery center, and the hospital outpatient department. Migrating eligible cases into a well-contracted ASC captures a facility fee the office cannot bill, while implantable devices — spinal cord stimulators and intrathecal pumps — and in-office or reference urine drug testing (UDT) add high-value, high-scrutiny ancillary revenue.
At the same time, the base is under pressure. Payers have tightened local coverage determinations and imposed injection frequency caps, prior authorization now gates most interventional procedures, UDT coverage has been sharply curtailed, and opioid-prescribing oversight adds regulatory risk. PE- and MSO-backed consolidation has raised the stakes on every point of the contract. The same procedure mix can be worth radically different amounts depending on how it is sited, coded, and negotiated — and that is precisely where Fulcrum works.
Illustrative comparison. Replace with your confirmed figures before launch; reflects public CMS site-of-service, ASC, and commercial payer methodology, 2024–2026.
